GCP
CBIO

GSA Capital Partners’s Crescent Biopharma CBIO Stock Holding History

GSA Capital Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-837
Closed -$14K – 1753
2024
Q3 		$14K Buy
+837
New +$17.6K ﹤0.01% 1535
2024
Q2 		– Sell
-183
Closed -$55K – 1782
2024
Q1 		$55K Sell
183
-1,827
-91% -$546K ﹤0.01% 1529
2023
Q4 		$474K Buy
2,010
+1,072
+114% +$167K 0.04% 830
2023
Q3 		$141K Buy
+938
New +$148K 0.01% 1352
2022
Q1 		– Sell
-1,461
Closed -$210K – 1555
2021
Q4 		$210K Buy
+1,461
New +$265K 0.03% 1185
2020
Q2 		– Sell
-238
Closed -$54K – 798
2020
Q1 		$54K Buy
238
+84
+55% +$32.1K 0.01% 956
2019
Q4 		$82K Buy
+154
New +$83.4K 0.01% 1352
2019
Q3 		– Sell
-155
Closed -$185K – 1503
2019
Q2 		$185K Buy
+155
New +$185K 0.02% 1260
2019
Q1 		– Sell
-215
Closed -$204K – 1529
2018
Q4 		$204K Buy
+215
New +$259K 0.02% 1096
2018
Q1 		– Sell
-867
Closed -$1.46M – 1682
2017
Q4 		$1.46M Buy
+867
New +$1.15M 0.09% 374

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

GSA Capital Partners's CBIO Position: Q4 2024 in Review

GSA Capital Partners sold out of Crescent Biopharma (CBIO) in Q4 2024, closing a stake of 837 shares — an estimated $14K sold.

GSA Capital Partners first reported a position in CBIO in Q4 2017 and held it in 10 quarters. The position peaked at $1.46M in Q4 2017. 41 funds tracked by Wall St. Rank hold CBIO as of Q4 2024.

  • GSA Capital Partners reported no remaining Crescent Biopharma position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 837 Crescent Biopharma shares in Q4 2024, an estimated $14K.
  • GSA Capital Partners first reported a position in Crescent Biopharma in Q4 2017 and held it in 10 quarters.
  • GSA Capital Partners's Crescent Biopharma position peaked at $1.46M in Q4 2017.
  • 41 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.